Help oversee talent in skills competition
Sign up to be a workshop supervisor at WorldSkills London 2011
Bringing together 1,000 young people from across the globe, the event see will the youngsters compete for medals in 45 categories across six sectors, including manufacturing (and engineering) technology, construction and building technology and transportation and logistics.
WorldSkills London 2011 takes place from 5-8 October at ExCeL London and manufacturing professionals are needed to help as workshop supervisors, who will be responsible for the preparation of materials, health and safety, security and workshop upkeep. They will also support the international judging panel as they test the competitors.
Signing up for the job requires a commitment of approximately one day per month for the next year, increasing to two or three days a month in the six months leading up to the competition and full-time for 10-12 days during the competition. Accommodation, expenses and a remuneration package are available to those who sign up.
Executive director of WorldSkills London 2011, Aidan Jones said: ‘Skills shape our world and workshop supervisors will play an essential role in this massive demonstration of the next generation of talent.’
You may also like
Manufacturing
Sharp boosts autoinjector and pen assembly line capability with $20m investment in Pennsylvania facility
The money will boost its autoinjector and pen assembly, labelling and packaging lines across various therapeutic areas at its facility in Macungie, meeting the rising demand for injectables
Research & Development
Simris Biologics secures €200K funding to develop microcystin-based payloads for antibody-drug conjugates
The Berlin-based subsidiary will use the grant to advance the KlicMic R&D programme, creating targeted microcystin payloads for ADCs that aim to improve cancer therapy efficacy whilst reducing side effects
Research & Development
Merck scraps £1bn UK expansion amid concerns as warnings mount over UK’s life sciences competitiveness
The company cited underinvestment in life sciences and the undervaluation of innovative medicines for the decision, raising questions about the UK’s competitiveness in pharmaceutical research and production